LCDX Caliber Imaging and Diagnostics Inc (CE)

Caliber Imaging & Diagnostics (OTCQB:LCDX), formerly Lucid, Inc., has appointed Joseph R. Williams as Vice President of Global Marketing, a newly created position, effective immediately.

Mr. Williams has more than three decades of experience in healthcare marketing, product and business development. Before arriving at Caliber I.D., Mr. Williams was Director of Market Development at Axsun Technologies/Volcano Corporation, where he led the creation and execution of strategies focused on the development and application of Optical Coherence Tomography (OCT) and other imaging technologies. Prior to this, he was Senior Director of Global Marketing-Neurosurgery Division at Integra Life Sciences, where he was responsible for all marketing and strategic planning activities. Earlier, he served as Director of Global Marketing-Visualization Products Division at Smith & Nephew Endoscopy, where he oversaw global strategic sales, marketing, operations and R&D. Prior to this, he held positions at Olympus America, Inc. and Welch Allyn. He holds an MBA degree in business management from the University of Rochester, an MS degree in medical biology from Long Island University and a BS degree in biology from St. John's University.

Mr. Williams said, "With more and more patients around the world undergoing screening for skin cancers, it is imperative that the global medical community be aware of the latest technical advances in the field. I believe that Caliber I.D.'s VivaScope® system offers a tremendous advantage for physicians and patients alike. As Vice President of Global Marketing, I intend to develop strategies in tandem with company management to broaden awareness of VivaScope among healthcare providers worldwide."

L. Michael Hone, Chief Executive Officer of Caliber I.D., said, "Joe brings a tremendous amount of industry experience and talent to Caliber I.D., and we are truly fortunate to have him helping to shape our global marketing efforts. I am confident his experience and insights in healthcare marketing will allow us to expand VivaScope's influence and sales internationally."

About Caliber Imaging & Diagnostics

Caliber Imaging & Diagnostics' proprietary, cutting-edge VivaScope(R) system is a disruptive, noninvasive point-of-care platform imaging technology with numerous applications in dermatology, surgery and research. FDA 510(k) cleared, VivaScope has regulatory approval in most major markets. With 78 issued or pending patents worldwide, VivaScope significantly improves outcomes and reduces costs, allowing physicians to quickly detect cancerous lesions that appear benign. VivaScope dramatically reduces the need for expensive, painful and time-consuming biopsies, which show no malignancy approximately 70% of the time. VivaScope also has significant applications in testing and analysis in the cosmetics industry. For more information about Caliber I.D. and its products, please visit www.caliberid.com.

VivaScope(R) is a registered trademark of Caliber Imaging & Diagnostics.

Safe Harbor

This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995, including the statements regarding the potential for future product revenue growth and financial performance. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the 2013 10-K filed by us with the Securities and Exchange Commission.

CONTACT: Company Contact:
         Richard Christopher
         Chief Financial Officer
         (617) 348-9821
         
         Investor Relations Contact:
         LHA
         Kim Sutton Golodetz
         (212) 838-3777
         kgolodetz@lhai.com
         
         Public Relations Contacts:
         Dian Griesel Int'l.
         Susan Forman or Laura Radocaj
         (212) 825-3210
         sforman@dgicomm.com
         lradocaj@dgicomm.com